{"name":"Cabaletta Bio","slug":"cabaletta-bio","ticker":"","exchange":"","domain":"","description":"Cabaletta Bio is a clinical-stage biotechnology company focused on developing engineered T cell therapies for the treatment of B cell-mediated autoimmune diseases. The company's lead product candidate, CABA-201, is in Phase 1/2 clinical trials for the treatment of mucocutaneous pemphigus, a severe and potentially life-threatening autoimmune disease.","hq":"","founded":0,"employees":"N/A","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":142674000,"netIncome":-167856000,"cash":82982000,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.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?oc=5","date":"2026-03-24","type":"pipeline","source":"simplywall.st","summary":"Will Cabaletta Bio (NASDAQ:CABA) Spend Its Cash Wisely? - simplywall.st","headline":"Will Cabaletta Bio (NASDAQ:CABA) Spend Its Cash Wisely?","sentiment":"neutral"},{"date":"2026-03-23","type":"earnings","source":"SEC EDGAR","summary":"10-K filed with SEC: 10-K","headline":"Annual Report (10-K) Filed","sentiment":"neutral"},{"date":"2026-03-23","type":"regulatory","source":"SEC EDGAR","summary":"8-K filed with SEC: 8-K","headline":"SEC 8-K: 8-K","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiswJBVV95cUxQcmQyX25HOWRGYkYtbFhYMWhqbS1GdTd1ekI2N1BSUXN0ckVMQ3poSFFDNHMteUJhaEhod0tyNWR3eDJZRVp0bEpIbjNfVjNPVlJXUG1zbHM4T2dFaW1wUFRPUnRPYUVpTW1UX2NWYkpmcjBmX0Y0TDcwVERCMXFpTFd4a2c1bDM5U2ZxR2FGM3BzNENqazlwNWJhQ1dKYmJUUEhyN1JzZTR1YnRhOGpjMFd0M0ZhNUNQakJtWWJrQ3FjbEpPRkhVZ29ONUk5bS12TVJtek1FOVlzN0FxUGhLRThOWXJMMThpbW1YUEMzRHg2QVN6bUxrYVR4UnVXU2QwSTNaem5MbjU0UnRCSzJjQ0RvSXhHZkllY1g5S3NhN3FXSHB0aWZUTURzQ19RUlM1SlVB?oc=5","date":"2026-03-10","type":"pipeline","source":"PR Newswire","summary":"CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncology Pipelines Accelerate | DelveInsight - PR Newswire","headline":"CD19 Inhibitors Market to Witness Significant Expansion During the Forecast Period (2025-2034) as Autoimmune and Oncolog","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxQZ1o1elJlMGFsNG9rUDVqMGFIRF9zaDEyYUl0WGhqTGFJdFVaUDYtWm5ySzRNbnJRMS1SVTl1MXZCeVo4LU1WdzhUdXhySmIxTlVqeDFmTlZiVGlJUFl6aWZEbmRiNlhpS1hBQkV3VC1xQVRHamZZTE1lU0VjcG9SMnBjanE2aGl4dEVxaA?oc=5","date":"2026-02-27","type":"pipeline","source":"BioSpace","summary":"Deep Dive: BioSpace Takes On JPM26 in San Francisco - BioSpace","headline":"Deep Dive: BioSpace Takes On JPM26 in San Francisco","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-01-26","type":"pipeline","source":"simplywall.st","summary":"Can Cabaletta Bio’s (CABA) Shift To Automated CAR T Manufacturing Redefine Its Scalability Edge? - simplywall.st","headline":"Can Cabaletta Bio’s (CABA) Shift To Automated CAR T Manufacturing Redefine Its Scalability Edge?","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihwFBVV95cUxQRThoSE5oRWpsQzdDVEZrZEhHR0d0TnZwYXZNM3NhYkVzLVR4SWlYcXprQUVxd1EyTDdWSVljY2h1SGgyN0F4czFQbFBabk0wSUFDeWNPR2N6d2pUM3ZiVzJxbU11VXZpbENKbXZZVWtSV3o3clZZemFTb0JzTFljM2lkMDcyRXc?oc=5","date":"2025-12-01","type":"pipeline","source":"BioSpace","summary":"6 Companies Hanging On in Cell Therapy - BioSpace","headline":"6 Companies Hanging On in Cell Therapy","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE95TFE3ckRvaGFHeFB3TDE4TlRPc3RfTTB2Rm9ZR050RlZ3Q0lVbkVBRDRLOUxnNGEzY09xY3JzcUI5dUhGTTlmdkFhamRLRVNQSnZ4TFA0VDJ4bFpyODdJSElVaHpRVHhsVjFBZ2RBdE5ubG5tLXc?oc=5","date":"2025-11-19","type":"pipeline","source":"Labiotech.eu","summary":"Eight CAR-T cell therapy companies you should know about - Labiotech.eu","headline":"Eight CAR-T cell therapy companies you should know about","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxOdkVfeHRndnNTODdCSHRubXpwY2xvaWJ4UWxsZDd5cl96RHFNTzkwUnYzZ3V1TGJLbnU4ZWswZGNqR0dGUTZzdEhmOWRnZWdTb0F5bW1aQ01UOUxFZmg3T0lINThzUjZmcGtWbktJaGVTSjlzY1M3UXhzbjJYdDhtTWNOOE9YNkRka2JfWmZFbTVDbVZjZkhZT0paYmQybzc0bURZdmFBVUNES0U?oc=5","date":"2025-10-17","type":"pipeline","source":"Fierce Biotech","summary":"Cabaletta corrals cell therapy Legend—Chutes & Ladders - Fierce Biotech","headline":"Cabaletta corrals cell therapy Legend—Chutes & Ladders","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitAFBVV95cUxPR2VpOHFiTmdVZ0pCZldIT2lNNHlyREN0bU40elkxekhXUHFyeFJvRm9iZDhTbHgwRm5sYlNzRmpYOUdFN0dnRjlPTkhXb2xsTHBGb2VLaWdnTWk4NWlxY2gzTnY5aTFvdlR0MmtxcFJPZEFCMGdXQ25VLURMVmRKOHdlZElNNmplSjdxV29UX2VBQ1luc2RJMVlvZ0x2czYyZWtkTlB6dDJhRTFfS2pORDYzZEQ?oc=5","date":"2025-10-17","type":"trial","source":"Endpoints News","summary":"Boehringer Ingelheim names global obesity leader; Calico taps AbbVie vet for discovery role - Endpoints News","headline":"Boehringer Ingelheim names global obesity leader; Calico taps AbbVie vet for discovery role","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxQbktKWHd5aHNuZ0lncUU5RzNuYXdSZlhqRW9hYlVKT3JmcjB1enNCX29kUDB0Y0VsQjhYRkdkUTZVYTJGb29iY2FINnFfZks3dTFnd0ppbGRQY1NUYWxrRTRCejdsa3IwM3ZncGhQeUEtaVdzWVFwaFZtMEt4bDNXdzd2V01JUEFPeDlYQkZSNGpvYU1DS1paazVGaw?oc=5","date":"2025-10-14","type":"pipeline","source":"Fierce Pharma","summary":"Cabaletta picks up the pace with new commercial chief from Legend, Celgene - Fierce Pharma","headline":"Cabaletta picks up the pace with new commercial chief from Legend, Celgene","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxPNEJVc2owMHFhdGh5eWFYWE1iYzc1S24tWjE1WFZ1U1B4ak5PNXpDMEp6M3JQNzBrdUhCUjFrSlJUby1QVThpSkJ6V3gteW5YZWM0SUxTZ0VCNlpBcnlmNlJKVExtamRWNVlaanhHZ0RmcEZmQmpkMEE3dVVZbjhWTW1YeW9yNVZKTzFIZnhzZGUxaWpyWk5tYlFkUDFJVlF6UkhrX1JicUpSaXRrZy16MG45MGdBcWRpMjd0aVhVbmI1cVd5VUE?oc=5","date":"2025-10-10","type":"trial","source":"Fierce Biotech","summary":"Cabaletta CAR-T wipes out B cells without preconditioning in small autoimmune trial - Fierce Biotech","headline":"Cabaletta CAR-T wipes out B cells without preconditioning in small autoimmune trial","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMingFBVV95cUxNcjhPOUxuT2RJX09GbWdCUF9aeVk5Qmk4c0lBUGh1TmxVU1RsN1lvZFlXdXphd2lFOS01RFNnbkFLV2ExclNoekpISVA5OC1rcFBaSFdRYzhZanIzbkRWLWsxZFJ6QUhZNVFXUlAyS2ljQnlYczdSSUdoUURJLWx1QVkwazR6WlBBMkNYdDhCbVlBWnh5dGF5S1hqZWtYdw?oc=5","date":"2024-06-17","type":"trial","source":"BioPharma Dive","summary":"New data showcase promise, growing pains of CAR-T in autoimmune disease - BioPharma Dive","headline":"New data showcase promise, growing pains of CAR-T in autoimmune disease","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxOWlZ4MWVYWmRIdmVDRENfbC1vb2NaZ0dOZTZLYWFBYVRFRDJhM05ORzBaQ2FubWFCMFdYeGRVc3dBSDJDYUtfSW5EN0k3SGNuQ3dXdGNUaGM4WGUwWTg3aUZLNk9kOWVoVDFETWJ2VUhyX1hJNjl1QWhaelA4WDFqcmUwVW9ZUVltTml3QjhObzVQYmFySlota3BLS0M?oc=5","date":"2023-11-06","type":"deal","source":"Contract Pharma","summary":"Cellares, Cabaletta Bio Partner on Automated Manufacturing Platform - Contract Pharma","headline":"Cellares, Cabaletta Bio Partner on Automated Manufacturing Platform","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":3,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":{"source":"sec_edgar+yahoo","revenue":null,"revenuePeriod":null,"revenueHistory":[],"grossProfit":null,"grossProfitHistory":[],"rdSpend":142674000,"rdSpendHistory":[],"sgaSpend":null,"operatingIncome":null,"operatingIncomeHistory":[],"netIncome":-167856000,"netIncomeHistory":[],"eps":null,"epsHistory":[],"cash":82982000,"cashHistory":[],"totalAssets":165083000,"totalLiabilities":null,"totalDebt":null,"equity":null,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":null,"capexHistory":[],"freeCashflow":null,"dividendsPaid":null,"buybacks":null,"employees":null,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":null}